08:38 AM EDT, 06/06/2025 (MT Newswires) -- BioCryst Pharmaceuticals ( BCRX ) said Friday its Orladeyo drug has been approved for reimbursement by the Netherlands for the routine prevention of hereditary angioedema attacks in patients aged 12 years and up.

The approval followed a positive recommendation from the Zorginstituut Nederland, the company said.

"It means that patients and physicians across all major European countries now have access to a modern, oral prophylactic option to help prevent hereditary angioedema attacks," said Abid Karim, general manager of Europe at BioCryst.

Hereditary angioedema can lead to severe swelling attacks.